{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:12:19Z","timestamp":1790064739374,"version":"4.0.1"},"reference-count":23,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"unspecified","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma K.K.","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,1,2]]},"DOI":"10.1080\/14656566.2019.1685500","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T17:50:19Z","timestamp":1572976219000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin"],"prefix":"10.1080","volume":"21","author":[{"given":"Tomoko","family":"Hayashi","sequence":"first","affiliation":[{"name":"Medical Division, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Murayama","sequence":"additional","affiliation":[{"name":"Medical Division, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Shinfuku","sequence":"additional","affiliation":[{"name":"Regulatory Office Japan, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Regulatory Office Japan, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tsumiyama","sequence":"additional","affiliation":[{"name":"Japan Development, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotsugu","family":"Oyama","sequence":"additional","affiliation":[{"name":"Medical Division, Novartis Pharma K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031907"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1441"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1732"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00684.x"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00859.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1058090"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.006"},{"key":"cit0008","first-page":"2593","volume":"61","author":"Odawara M","year":"2012","journal-title":"J New Rem Clin"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12252"},{"key":"cit0010","unstructured":"Pharmaceuticals and Medical Devices Agency. Vildagliptin (EQUA) package insert. [cited 2018 Oct 2]. Available from: http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/300242_3969011F1020_1_21.pdf [in Japanese]."},{"key":"cit0011","unstructured":"Japan Diabetes Clinical Data Management Study Group. 2013. Available from: http:\/\/jddm.jp\/data\/index-2016.html"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12436"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1404576"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0059-x"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.004"},{"key":"cit0016","unstructured":"European Medicines Agency. Galvus (vildagliptin). Summaries of product characteristics. 2012 [cited 2018 Jul 31] Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000771\/WC500020327.pdf"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0147-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2874w"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03031.x"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1019609"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-1188"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0033-2"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1420165"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2019.1685500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:16:19Z","timestamp":1620465379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1685500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,2]]}},"alternative-id":["10.1080\/14656566.2019.1685500"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2019.1685500","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}